|Bid||39.05 x 900|
|Ask||39.20 x 800|
|Day's Range||38.01 - 39.42|
|52 Week Range||32.44 - 76.45|
|Beta (5Y Monthly)||1.85|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cathie Wood looks for stocks that are leading innovators. But the stocks that fit that mold aren't always leaders when it comes to delivering huge returns over the short term. On the contrary, quite a few of the stocks in Wood's Ark Invest portfolios have been big losers.
Does Intellia Therapeutics, Inc. (NTLA) have what it takes to be a top stock pick for momentum investors? Let's find out.
The consensus price target hints at an 115.1% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 17.02% and 4.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
The popular growth investor has stumbled after a hot start to 2023, but Wood keeps adding to some of her favorite positions.
These stocks have some promising growth opportunities, but they also come with a fair amount of risk.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the treatment of hereditary angioedema.
Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Exelixis (NASDAQ: EXEL), and Intellia Therapeutics (NASDAQ: NTLA). Prosper Junior Bakiny (CRISPR Therapeutics): Unprofitable clinical-stage biotech companies got hammered last year. Gene-editing specialist CRISPR Therapeutics fits that description to a T, so it got dragged down along with the broader market.
There are no guarantees that any stock will generate huge returns. But the odds look pretty good for these three growth stocks.
Cathie Wood's favorite stocks have been synonymous with growth, and although many of them have been struggling of late, there are a couple that have tripled in value in the past three years: Tesla (NASDAQ: TSLA) and Intellia Therapeutics (NASDAQ: NTLA). Since March 2020, shares of Tesla have soared 334%. Tesla also ended up joining the S&P 500 late in 2020 in a sign of its growing stability.
Shares of the gene-editing pioneer Intellia Therapeutics (NASDAQ: NTLA) rose by 17.5% through the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. There are currently eight medications approved by the FDA to prevent and/or treat HAE attacks. NTLA-2002, however, could be the first genetic medicine for this indication (depending on its ongoing clinical trials).
Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 0% and 11.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here is how Intellia Therapeutics, Inc. (NTLA) and Centogene N.V. (CNTG) have performed compared to their sector so far this year.
Gene-editing biotech companies are showing the potential to cure diseases. The Food and Drug Administration (FDA) could approve the first CRISPR gene-editing therapy this year -- exa-cel, developed by CRISPR Therapeutics and Vertex Pharmaceuticals -- to treat severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TBT), a blood disorder associated with anemia. Two others to watch for with solid long-term prospects are Beam Therapeutics (NASDAQ: BEAM) and Intellia Therapeutics (NASDAQ: NTLA).
Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Growth stocks had an exceptionally rough 2022. Supply chain woes, sky-high inflation, rising interest rates, and the conflict in Ukraine all conspired last year to spur a major correction across the growth equity landscape. In turn, Wall Street analysts think there are some tremendous bargains within this space right now.
Analysts are bearish, for example, on the three stocks that have helped the most in Wood's Ark Innovation ETF (NYSEMKT: ARKK) trouncing the market so far in 2023. Here are three Cathie Wood stocks that could more than double in 12 months, according to Wall Street. Wood owns shares of Intellia Therapeutics (NASDAQ: NTLA) in two of her ETFs -- the flagship Ark Innovation ETF and the Ark Genomic Revolution ETF (NYSEMKT: ARKG).
The mean of analysts' price targets for Intellia Therapeutics, Inc. (NTLA) points to a 145.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Cathie Wood is roaring back. Her flagship ARK Innovation ETF (NYSEMKT: ARKK) plunged 67% last year. But so far in 2023, the exchange-traded fund is up nearly 40%. This impressive performance could be just the warm-up.
Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.
The consensus price target hints at an 185.4% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.